Studies have shown that wogonin could effectively combat chemoresistance in the Adriamycin (ADR)-induced resistant human chronic myelogenous leukemia (CML) K562/A02 and potentiated the inhibitory effect of ADR on leukemia in vivo through inhibiting Nrf2 signaling by Stat3/NF-kB inactivation 59. This evidence concerns the gene STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive.